Skip to main content

Generic Vabomere Availability

Last updated on Oct 6, 2021.

Vabomere is a brand name of meropenem/vaborbactam, approved by the FDA in the following formulation(s):

VABOMERE (meropenem; vaborbactam - powder;intravenous)

  • Manufacturer: REMPEX
    Approval date: August 29, 2017
    Strength(s): 1GM/VIAL;1GM/VIAL [RLD]

Has a generic version of Vabomere been approved?

No. There is currently no therapeutically equivalent version of Vabomere available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vabomere. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical compositions comprising cyclic boronic acid ester derivatives
    Patent 10,172,874
    Issued: January 8, 2019
    Assignee(s): REMPEX PHARMACEUTICALS, INC.

    Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

    Patent expiration dates:

    • August 8, 2031
      ✓ 
      Drug product
  • Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
    Patent 10,183,034
    Issued: January 22, 2019
    Assignee(s): Rempex Pharmaceuticals, Inc.

    Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

    Patent expiration dates:

    • August 8, 2031
      ✓ 
      Patent use: TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
  • Patent 10,561,675

    Patent expiration dates:

    • August 8, 2031
      ✓ 
      Patent use: TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
  • Patent 11,007,206

    Patent expiration dates:

    • August 8, 2031
      ✓ 
      Patent use: TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED
  • Cyclic boronic acid ester derivatives and therapeutic uses thereof
    Patent 8,680,136
    Issued: March 25, 2014
    Assignee(s): Rempex Pharmaceuticals, Inc.

    Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to 1 cyclic boronic acid ester derivatives and their use as therapeutic agents.

    Patent expiration dates:

    • August 29, 2031
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Cyclic boronic acid ester derivatives and therapeutic uses thereof
    Patent 9,694,025
    Issued: July 4, 2017
    Assignee(s): Rempex Pharmaceuticals, Inc.

    Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

    Patent expiration dates:

    • August 8, 2031
      ✓ 
      Patent use: TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • August 29, 2022 - NEW CHEMICAL ENTITY
    • August 29, 2027 - GENERATING ANTIBIOTIC INCENTIVES NOW

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.